

Lie introdul for the sole use of the

Ambros 13

The information in this facsimile is confidential and is intended for the sole use of the addressee designated below. If this facsimile has been misdirected, kindly return it by postal service to Gilead Sciences, Inc. If you do not receive all pages clearly, please telephone (650) 573-4709 or 572-6535.



GILEAD SCIENCES, INC. 333 Lakeside Drive

Foster City, California 94404
Telephone: 650/572-6535 or 650/574-3000

Telefacsimile: 650/573-4899 (Patents) or 650/578-9264

Date:

April 10, 1998

Telefax: (703) 308-7921

To:

Assistant Commissioner

for Patents

Washington, D.C. 20231

Re: In re application of: Arimilli et al

Serial No.: 08/900,746 Filed: July 25, 1997

RECEIVED

MAY 2 0 1998

Attorney Docket No. 221.P1

Group No. 1613

Examiner: M. Ambrose

FoPublishing@ME@TIDE ANALOGS Corres/Allowed Files (10)

From:

Daryl D. Muenchau, Reg. 36,616

Jary DM ven chan

Total Number of Pages Including Cover Sheet:

85*

*Due to size, facsimile is being sent in 3 separate transmissions:

- 1) Fax transmittal through Jones et al.
- 2) Krise et al, through John A. Landgrebe
- 3) Starrett et al, through Tsai et al.

Certification of Facsimile Transmission

I hereby certify that this paper along with the following documents are being facsimile transmitted to the Patent and Trademark Office and that the original documents are being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

Attorney Docket No. 221.P1

APR 1 3 1998

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Arimilli et al.

Serial No.: 08/900,746

Group No.: 1205

Filed:

July 25, 1997

Examiner:

unassigned

For:

NUCLEOTIDE ANALOGS

Assistant Commissioner for Patents

Washington, D.C. 20231

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS OF FILING OR BEFORE MAILING OF FIRST OFFICE ACTION (37 CFR 1.97 (b))

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited on the date shown below with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

(check and complete appropriate item below);		
37 CFR 1.8 (a) x with sufficient postage as first class mail	ōī	37 CFR 1.10 as "Express Mail Post Office to Addressee" Mailing Label No.
	——————————————————————————————————————	Robin Torres pe or print name of person mailing paper)
Date: 17 auch 4,1798		- Ratin Toises
	(Si	gnature of person mailing paper)

COPY

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97 (b).

Reg. No. 36,616	SIGNATURE OF AGENT	
•	SIGNAPURE OF AGENT	
Tel. No.: (650) 573-4712	Daryl D. Muenchau	
	Type or print name of agent	
	Gilead Sciences, Inc.	
	333 Lakeside Drive	
	P.O. Address	•
	Foster City, CA 94404	

A STATE OF THE STA





Attorney Docket No. 221.P1

COPY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Arimilli et al.

Serial No.: 08/900,746

Group No.: 1205

Filed:

July 25, 1997

Examiner: unassigned

For:

NUCLEOTIDE ANALOGS

Assistant Commissioner for Patents

Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT (modified)

List of Sections Forming Part of This Information Disclosure Statement.

The following sections are being submitted for this Information Disclosure Statement:

- 1. x Preliminary Statements
- 2. X FORM PTO 1449 (Modified)
- 3. X Copies of Listed Information Items Accompanying This Statement

Section 1. Preliminary statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97 (g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

		Robin Torres
		(Type or print name of person mailing paper)
Date:	March 4 1998	Robin Sorres
_	'	(Signature of person mailing paper)

Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed in Form PTO-1449 accompany this information statement.

Reg. No. 36,616

Tel. No.: (650) 573-4712

Daryl D. Muenchau

Type or print name of agent

Gilead Sciences, Inc. 333 Lakeside Drive P.O. Address

Foster City, CA 94404